Aspen Bids To Buy Thrombosis Drugs, Production Plant From GSK
This article was originally published in PharmAsia News
Executive Summary
Aspen Pharmacare has made a bid to acquire GlaxoSmithKline's line of thrombosis drugs as well as their production plant that could add more than $400 million a year to revenues.